These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 19795182)

  • 41. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans.
    de Vries T; Villalón CM; MaassenVanDenBrink A
    Pharmacol Ther; 2020 Jul; 211():107528. PubMed ID: 32173558
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serotonin in migraine: theories, animal models and emerging therapies.
    Johnson KW; Phebus LA; Cohen ML
    Prog Drug Res; 1998; 51():219-44. PubMed ID: 9949863
    [TBL] [Abstract][Full Text] [Related]  

  • 43. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomized, controlled trial of telcagepant for the acute treatment of migraine.
    Nardin R
    Neurology; 2010 Mar; 74(12):1007; author reply 1007-8. PubMed ID: 20308688
    [No Abstract]   [Full Text] [Related]  

  • 45. Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial.
    Connor KM; Aurora SK; Loeys T; Ashina M; Jones C; Giezek H; Massaad R; Williams-Diaz A; Lines C; Ho TW
    Headache; 2011 Jan; 51(1):73-84. PubMed ID: 21070230
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Side effects associated with current and prospective antimigraine pharmacotherapies.
    González-Hernández A; Marichal-Cancino BA; MaassenVanDenBrink A; Villalón CM
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):25-41. PubMed ID: 29226741
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Selective inhibition of 5-HT7 receptor reduces CGRP release in an experimental model for migraine.
    Wang X; Fang Y; Liang J; Yin Z; Miao J; Luo N
    Headache; 2010 Apr; 50(4):579-87. PubMed ID: 20236348
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New targets in the acute treatment of headache.
    Goadsby PJ
    Curr Opin Neurol; 2005 Jun; 18(3):283-8. PubMed ID: 15891413
    [TBL] [Abstract][Full Text] [Related]  

  • 49. CGRP receptor antagonism and migraine therapy.
    Edvinsson L; Warfvinge K
    Curr Protein Pept Sci; 2013 Aug; 14(5):386-92. PubMed ID: 23745702
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drugs targeting nitric oxide synthase for migraine treatment.
    Barbanti P; Egeo G; Aurilia C; Fofi L; Della-Morte D
    Expert Opin Investig Drugs; 2014 Aug; 23(8):1141-8. PubMed ID: 24818644
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
    Hargreaves R; Olesen J
    Headache; 2019 Jun; 59(6):951-970. PubMed ID: 31020659
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics and pharmacodynamics of new acute treatments for migraine.
    Lupi C; Benemei S; Guerzoni S; Pellesi L; Negro A
    Expert Opin Drug Metab Toxicol; 2019 Mar; 15(3):189-198. PubMed ID: 30714429
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 5-HT1F receptor agonists in acute migraine treatment: a hypothesis.
    Ramadan NM; Skljarevski V; Phebus LA; Johnson KW
    Cephalalgia; 2003 Oct; 23(8):776-85. PubMed ID: 14510923
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Emerging target-based paradigms to prevent and treat migraine.
    Silberstein SD
    Clin Pharmacol Ther; 2013 Jan; 93(1):78-85. PubMed ID: 23212108
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Migraine: Experimental Models and Novel Therapeutic Approaches.
    Tardiolo G; Bramanti P; Mazzon E
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31208068
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An oral calcitonin gene-related peptide receptor antagonist for acute migraine management: sign of a possible new chapter in headache medicine.
    Garza I
    Curr Neurol Neurosci Rep; 2009 Mar; 9(2):91-3. PubMed ID: 19268029
    [No Abstract]   [Full Text] [Related]  

  • 57. Drugs targeting 5-hydroxytryptamine receptors in acute treatments of migraine attacks. A review of new drugs and new administration forms of established drugs.
    Tfelt-Hansen PC; Pihl T; Hougaard A; Mitsikostas DD
    Expert Opin Investig Drugs; 2014 Mar; 23(3):375-85. PubMed ID: 24289494
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The role of serotonin and serotonin receptors in the pathogenesis of migraine and in the mechanisms of action of anti-migraine drugs].
    Amelin AV; Skoromets AA; Ignatov IuD
    Zh Nevrol Psikhiatr Im S S Korsakova; 2000; 100(7):55-8. PubMed ID: 10957805
    [No Abstract]   [Full Text] [Related]  

  • 59. Lasmiditan for the treatment of migraine.
    Capi M; de Andrés F; Lionetto L; Gentile G; Cipolla F; Negro A; Borro M; Martelletti P; Curto M
    Expert Opin Investig Drugs; 2017 Feb; 26(2):227-234. PubMed ID: 28076702
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Therapeutic Impact of New Migraine Discoveries.
    Vécsei L; Lukács M; Tajti J; Fülöp F; Toldi J; Edvinsson L
    Curr Med Chem; 2019; 26(34):6261-6281. PubMed ID: 29848264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.